Xplan-2 with Head and Neck Localizer Model Hnl
Radionics
FDA Clearance Information
The xplan-2 with head and neck localizer was cleared by the FDA via the 510k pathway on August 30, 1999. Manufactured by Radionics, it is classified as a Class 2 device under product code MUJ.
What It Is
FDA-Cleared Indications
- Used for localization and treatment planning in head and neck clinical applications as described by the cleared device labeling.
Clinical Applications
- Preoperative localization and planning for head and neck procedures.
- Supporting surgical planning for head and neck tumors.
- Helping define the location of targeted anatomy during complex head and neck interventions.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The FDA record identifies the device category and intended application but does not provide detailed size, accessory, or compatibility specifications.
- Use requires trained clinical personnel and integration with the applicable imaging, planning, or surgical workflow.
- MRI safety should not be assumed; verify the device's current labeling and the specific localizer configuration before use in or near an MRI system.
- Inspect and handle the localizer according to the manufacturer's instructions, including any requirements for positioning, calibration, cleaning, or sterilization.
- Contraindications, limitations, and compatibility with newer imaging or navigation systems should be confirmed in the current manufacturer documentation.
Frequently Asked Questions
What are the clinical indications for xplan-2 with head and neck localizer?
The device is indicated for use in the planning and localization of head and neck surgical procedures, particularly in oncology settings.
What outcomes have been reported in clinical studies?
Studies report on workforce distribution, immune system roles in cancer, and surgical challenges during the COVID-19 pandemic, with a focus on survival and management strategies.
What complications have been reported?
Safety data indicate increased risks for elderly patients during the pandemic, highlighting the need for multidisciplinary management to mitigate infectious risks.